{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:46:26Z","timestamp":1792449986787,"version":"4.5.0"},"reference-count":117,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016934","name":"Troms\u00f8 Forskningsstiftelse","doi-asserted-by":"publisher","award":["(19_PET-NUKL)\/180\u00b0N\/N"],"award-info":[{"award-number":["(19_PET-NUKL)\/180\u00b0N\/N"]}],"id":[{"id":"10.13039\/100016934","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","award":["PR_TCL_2020-3"],"award-info":[{"award-number":["PR_TCL_2020-3"]}],"id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["(PRDNA234014GARA)"],"award-info":[{"award-number":["(PRDNA234014GARA)"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Cancer-associated fibroblasts (CAFs) are one of the main components of the tumor microenvironment (TME) of solid tumors. They have several functions, which all contribute to tumor growth and immune evasion. CAF presence is associated with poor clinical response to standard therapy and immunotherapy. However, its heterogeneity blunts their understanding and functionality. New analytical techniques are being applied to better understand their role in cancer. Meanwhile, CAF stratification and their immunomodulatory capabilities are the scope of many studies, also in the context of ionizing irradiation. In that regard, new immunotherapy strategies have set their sights on targeting CAF to modulate the TME into a more immune-stimulating environment. Among the different approaches, CAF depletion, reprogramming, and CAF-directed antibodies and cytokines can be distinguished, supported by substantial preclinical evidence and encouraging, but still preliminary clinical findings, mainly from early-phase (phase I) trials. Additionally, CAF-directed radionuclides have gained interest and are in clinical trials for therapeutic as well as diagnostic purposes. Here we summarize the studies and clinical developments of CAF-targeted therapies alone and in combination with radiotherapy.<\/jats:p>","DOI":"10.1136\/jitc-2024-009702","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:19Z","timestamp":1777914919000},"page":"e009702","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct01722149","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03932565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02198274","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05547321","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04939610","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05392205","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05180162","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04621435","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02209727","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06562192","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05098405","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04241276","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03307148","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03200847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01516216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02304419","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02008318","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03143985","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03834662","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00356460","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01472731","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03192345","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02517398","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04291079","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00834704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02045602","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00033215","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00033566","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00078390","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02117479","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03490669","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01900652","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00725634","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02529553","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04826003","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04857138","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03386721","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03875079","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05547321","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03307148","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04241276","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03520790","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03786094","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03168139","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04191421","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04999969","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03422536","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02082210","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02423343","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02734160","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02906397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01064622","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01479465","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01472198","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02715804","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03634332","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05077800","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06211335","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05637216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01821729","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02546531","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04331041","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-1427","authenticated-orcid":false,"given":"Eneko","family":"Garate-Soraluze","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, Centro de Investigacion Medica Aplicada, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Martinez-Zubiaurre","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, UiT The Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-2499","authenticated-orcid":false,"given":"Maria E","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[{"name":"Program of Immunology and Immunotherapy, Centro de Investigacion Medica Aplicada, Pamplona, Spain"},{"name":"Radiation Oncology, Clinica Universidad de Navarra Departamento de Oncologia Medica, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026050410151183000_14.5.e009702.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026050410151183000_14.5.e009702.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-025-02566-x","article-title":"Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review","volume":"11","author":"Masuda","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026050410151183000_14.5.e009702.3","doi-asserted-by":"crossref","DOI":"10.3390\/cells14171398","article-title":"Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications","volume":"14","author":"Badran","year":"2025","journal-title":"Cells"},{"key":"2026050410151183000_14.5.e009702.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1582532","article-title":"Revisiting the role of cancer-associated fibroblasts in tumor microenvironment","volume":"16","author":"Lan","year":"2025","journal-title":"Front Immunol"},{"key":"2026050410151183000_14.5.e009702.5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41417-021-00318-4","article-title":"Cancer-associated fibroblasts: overview, progress, challenges, and directions","volume":"28","author":"Ping","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"2026050410151183000_14.5.e009702.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02533-1","article-title":"Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications","volume":"25","author":"Huang","year":"2025","journal-title":"Mol Cancer"},{"key":"2026050410151183000_14.5.e009702.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.011"},{"key":"2026050410151183000_14.5.e009702.8","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00048.2019"},{"key":"2026050410151183000_14.5.e009702.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1"},{"key":"2026050410151183000_14.5.e009702.10","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0470-z"},{"key":"2026050410151183000_14.5.e009702.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01093-5","article-title":"Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?","volume":"21","author":"Martinez-Zubiaurre","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2026050410151183000_14.5.e009702.12","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-59"},{"key":"2026050410151183000_14.5.e009702.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40495-015-0044-8","article-title":"Potential of CXCR4\/CXCL12 Chemokine Axis in Cancer Drug Delivery","volume":"2","author":"Wang","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"2026050410151183000_14.5.e009702.14","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.180","article-title":"CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis"},{"key":"2026050410151183000_14.5.e009702.15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.radonc.2014.03.014","article-title":"Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells","volume":"111","author":"Al-Assar","year":"2014","journal-title":"Radiother Oncol"},{"key":"2026050410151183000_14.5.e009702.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820459116"},{"key":"2026050410151183000_14.5.e009702.17","first-page":"2192","article-title":"Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts","volume":"6","author":"Li","year":"2016","journal-title":"Am J Cancer Res"},{"key":"2026050410151183000_14.5.e009702.18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2991"},{"key":"2026050410151183000_14.5.e009702.19","doi-asserted-by":"crossref","DOI":"10.1038\/srep46714","article-title":"Ionizing radiation abrogates the pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts","volume":"7","author":"Grinde","year":"2017","journal-title":"Sci Rep"},{"key":"2026050410151183000_14.5.e009702.20","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2019.00070","article-title":"Impact of Cancer-Associated Fibroblast on the Radiation-Response of Solid Xenograft Tumors","volume":"6","author":"Steer","year":"2019","journal-title":"Front Mol Biosci"},{"key":"2026050410151183000_14.5.e009702.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3452"},{"key":"2026050410151183000_14.5.e009702.22","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e7","article-title":"A novel gene signature associated with poor response to chemoradiotherapy in patients with locally advanced cervical cancer","volume":"33","author":"Kim","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"2026050410151183000_14.5.e009702.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03656-5","article-title":"Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients","volume":"20","author":"Zhang","year":"2022","journal-title":"J Transl Med"},{"key":"2026050410151183000_14.5.e009702.24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/apm.12344","article-title":"The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma","volume":"123","author":"Matsuoka","year":"2015","journal-title":"APMIS"},{"key":"2026050410151183000_14.5.e009702.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.05.007"},{"key":"2026050410151183000_14.5.e009702.26","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(16)30067-5","article-title":"10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study","volume":"17","author":"van Maaren","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026050410151183000_14.5.e009702.27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17152484","article-title":"Cancer-Associated Fibroblasts: Immunosuppressive Crosstalk with Tumor-Infiltrating Immune Cells and Implications for Therapeutic Resistance","volume":"17","author":"Pawar","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050410151183000_14.5.e009702.28","doi-asserted-by":"publisher","DOI":"10.1002\/path.4103"},{"key":"2026050410151183000_14.5.e009702.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.03.004"},{"key":"2026050410151183000_14.5.e009702.30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001203"},{"key":"2026050410151183000_14.5.e009702.31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195300"},{"key":"2026050410151183000_14.5.e009702.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110"},{"key":"2026050410151183000_14.5.e009702.33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2019.09.013","article-title":"Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer","volume":"137","author":"Teramoto","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"2026050410151183000_14.5.e009702.34","doi-asserted-by":"crossref","unstructured":"Luo J , Xiang X , Gong G , et al . Cancer-associated fibroblast-mediated immune evasion: molecular mechanisms of stromal-immune crosstalk in the tumor microenvironment. Front Immunol 2025;16. doi:10.3389\/fimmu.2025.1617662","DOI":"10.3389\/fimmu.2025.1617662"},{"key":"2026050410151183000_14.5.e009702.35","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00262-015-1742-0","article-title":"Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma","volume":"64","author":"Takahashi","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2026050410151183000_14.5.e009702.36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature New Biol"},{"key":"2026050410151183000_14.5.e009702.37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.668731","article-title":"Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy","volume":"11","author":"Raskov","year":"2021","journal-title":"Front Oncol"},{"key":"2026050410151183000_14.5.e009702.38","doi-asserted-by":"publisher","DOI":"10.1002\/path.4824"},{"key":"2026050410151183000_14.5.e009702.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107701"},{"key":"2026050410151183000_14.5.e009702.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0688-7"},{"key":"2026050410151183000_14.5.e009702.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055146","article-title":"Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer","volume":"8","author":"Ino","year":"2013","journal-title":"PLoS ONE"},{"key":"2026050410151183000_14.5.e009702.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14060-x","article-title":"CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint","volume":"11","author":"Yu","year":"2020","journal-title":"Nat Commun"},{"key":"2026050410151183000_14.5.e009702.43","doi-asserted-by":"crossref","unstructured":"Chen M , Xiang R , Wen Y , et al . A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Sci Rep 2015;5. doi:10.1038\/srep14421","DOI":"10.1038\/srep14421"},{"key":"2026050410151183000_14.5.e009702.44","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1080\/21691401.2019.1687498","article-title":"Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models","volume":"47","author":"Chen","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2026050410151183000_14.5.e009702.45","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3892\/ol.2020.11637","article-title":"Antitumor immunity targeting fibroblast activation protein-\u03b1 in a mouse Lewis lung carcinoma model","volume":"20","author":"Xie","year":"2020","journal-title":"Oncol Lett"},{"key":"2026050410151183000_14.5.e009702.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109237"},{"key":"2026050410151183000_14.5.e009702.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01695.x"},{"key":"2026050410151183000_14.5.e009702.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2033"},{"key":"2026050410151183000_14.5.e009702.49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082658","article-title":"A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading","volume":"8","author":"Gottschalk","year":"2013","journal-title":"PLoS One"},{"key":"2026050410151183000_14.5.e009702.50","doi-asserted-by":"crossref","unstructured":"Li F , Zhao S , Wei C , et al . Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.958082","DOI":"10.3389\/fimmu.2022.958082"},{"key":"2026050410151183000_14.5.e009702.51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-25-0663","article-title":"Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors","volume":"14","author":"Bajbouj","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"2026050410151183000_14.5.e009702.52","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06144-0"},{"key":"2026050410151183000_14.5.e009702.53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2238"},{"key":"2026050410151183000_14.5.e009702.54","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026050410151183000_14.5.e009702.55","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"key":"2026050410151183000_14.5.e009702.56","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05842-5"},{"key":"2026050410151183000_14.5.e009702.57","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264544"},{"key":"2026050410151183000_14.5.e009702.58","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"},{"key":"2026050410151183000_14.5.e009702.59","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2025.1737443","article-title":"Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors","volume":"5","author":"Wu","year":"2025","journal-title":"Front Nucl Med"},{"key":"2026050410151183000_14.5.e009702.60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113354","article-title":"Oncolytic Adenovirus in Cancer Immunotherapy","volume":"12","author":"Peter","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026050410151183000_14.5.e009702.61","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"},{"key":"2026050410151183000_14.5.e009702.62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000238","article-title":"Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer","volume":"8","author":"Tr\u00fcb","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4001"},{"key":"2026050410151183000_14.5.e009702.64","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-21-0553"},{"key":"2026050410151183000_14.5.e009702.65","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"2026050410151183000_14.5.e009702.66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005282","article-title":"Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody","volume":"10","author":"Nadal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.67","doi-asserted-by":"crossref","first-page":"176374","DOI":"10.1016\/j.ejphar.2024.176374","article-title":"Retinoic acid signaling pathway in pancreatic stellate cells: Insight into the anti-fibrotic effect and mechanism","volume":"967","author":"Sun","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"2026050410151183000_14.5.e009702.68","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/biomedicines12061357","article-title":"Vitamin D3 (Calcitriol) Monotherapy Decreases Tumor Growth, Increases Survival, and Correlates with Low Neutrophil-to-Lymphocyte Ratio in a Murine HPV-16-Related Cancer Model","volume":"12","author":"Hern\u00e1ndez-Rangel","year":"2024","journal-title":"Biomedicines"},{"key":"2026050410151183000_14.5.e009702.69","doi-asserted-by":"crossref","DOI":"10.3390\/tomography11120143","article-title":"Cancer-Associated Fibroblasts: Clinical Applications in Imaging and Therapy","volume":"11","author":"Nilforoushan","year":"2025","journal-title":"Tomography"},{"key":"2026050410151183000_14.5.e009702.70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163022","article-title":"Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer","volume":"8","author":"Kitamura","year":"2023","journal-title":"JCI Insight"},{"key":"2026050410151183000_14.5.e009702.71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3158"},{"key":"2026050410151183000_14.5.e009702.72","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02347-z","article-title":"NADPH oxidase 1\/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts","volume":"10","author":"Amengual","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026050410151183000_14.5.e009702.73","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0710"},{"key":"2026050410151183000_14.5.e009702.74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3957"},{"key":"2026050410151183000_14.5.e009702.75","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19920-5","article-title":"TGF\u03b2-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts","volume":"11","author":"Grauel","year":"2020","journal-title":"Nat Commun"},{"key":"2026050410151183000_14.5.e009702.76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1504"},{"key":"2026050410151183000_14.5.e009702.77","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.IMM2016-B058","article-title":"Abstract B058: Development of AVID200, a novel and highly potent TGF-beta neutralizing immunotherapy","volume":"4","author":"O\u2019Connor-McCourt","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2026050410151183000_14.5.e009702.78","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1811605","article-title":"Pan-TGF\u03b2 inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade","volume":"9","author":"Greco","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026050410151183000_14.5.e009702.79","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13854","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGF\u03b2 inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1\/1b study","volume":"17","author":"Baranda","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026050410151183000_14.5.e009702.80","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-\u03b2 and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol Oncol"},{"key":"2026050410151183000_14.5.e009702.81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGF\u03b21 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026050410151183000_14.5.e009702.82","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411745","article-title":"Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting","volume":"24","author":"Radi\u0107","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026050410151183000_14.5.e009702.83","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02070-x","article-title":"PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models","volume":"40","author":"Morosi","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026050410151183000_14.5.e009702.84","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/CM9.0000000000003031","article-title":"Recent advances in cancer-associated fibroblast: Biomarkers, signaling pathways, and therapeutic opportunities","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2026050410151183000_14.5.e009702.85","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0192"},{"key":"2026050410151183000_14.5.e009702.86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18020288","article-title":"Matrix Metalloproteinases in Hepatocellular Carcinoma: Mechanistic Roles and Emerging Inhibitory Strategies for Therapeutic Intervention","volume":"18","author":"Dimesa","year":"2026","journal-title":"Cancers (Basel)"},{"key":"2026050410151183000_14.5.e009702.87","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82317"},{"key":"2026050410151183000_14.5.e009702.88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0205"},{"key":"2026050410151183000_14.5.e009702.89","doi-asserted-by":"crossref","unstructured":"Xiang H , Chan AG , Ahene A , et al . Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs 2021;13. doi:10.1080\/19420862.2021.1981202","DOI":"10.1080\/19420862.2021.1981202"},{"key":"2026050410151183000_14.5.e009702.90","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s10637-021-01146-x","article-title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody\u2013drug conjugate, in patients with advanced or metastatic cancer","volume":"39","author":"Kollmannsberger","year":"2021","journal-title":"Invest New Drugs"},{"key":"2026050410151183000_14.5.e009702.91","doi-asserted-by":"crossref","first-page":"109946","DOI":"10.1016\/j.radonc.2023.109946","article-title":"Stereotactic ablative radiotherapy and FAP\u03b1-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer","volume":"189","author":"Chen","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026050410151183000_14.5.e009702.92","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.110"},{"key":"2026050410151183000_14.5.e009702.93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211117","article-title":"Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma","volume":"14","author":"Gunderson","year":"2019","journal-title":"PLoS ONE"},{"key":"2026050410151183000_14.5.e009702.94","doi-asserted-by":"crossref","unstructured":"Chen J , Zhou Y , Pang Y , et al . FAP-targeted radioligand therapy with 68 Ga\/ 177 Lu-DOTA-2P(FAPI) 2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer 2025;13. doi:10.1136\/jitc-2024-010212","DOI":"10.1136\/jitc-2024-010212"},{"key":"2026050410151183000_14.5.e009702.95","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009852","article-title":"4-1BB agonist targeted to fibroblast activation protein \u03b1 synergizes with radiotherapy to treat murine breast tumor models","volume":"13","author":"Garate-Soraluze","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026050410151183000_14.5.e009702.97","doi-asserted-by":"crossref","unstructured":"Melero I , Tanos T , Bustamante M , et al . A first-in-human study of the fibroblast activation protein\u2013targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med 2023;15. doi:10.1126\/scitranslmed.abp9229","DOI":"10.1126\/scitranslmed.abp9229"},{"key":"2026050410151183000_14.5.e009702.98","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4717"},{"key":"2026050410151183000_14.5.e009702.99","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1158\/1078-0432.CCR-24-1562","article-title":"Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma","volume":"30","author":"Hansen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050410151183000_14.5.e009702.100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105374","article-title":"Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and\/or metastatic cervical squamous cell carcinoma","volume":"109","author":"Verlingue","year":"2024","journal-title":"EBioMedicine"},{"key":"2026050410151183000_14.5.e009702.101","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1158\/1078-0432.CCR-23-2677","article-title":"Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer","volume":"30","author":"Prenen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050410151183000_14.5.e009702.102","doi-asserted-by":"crossref","unstructured":"Kocher HM , Basu B , Froeling FEM , et al . Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun 2020;11. doi:10.1038\/s41467-020-18636-w","DOI":"10.1038\/s41467-020-18636-w"},{"key":"2026050410151183000_14.5.e009702.103","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"Oncoimmunology"},{"key":"2026050410151183000_14.5.e009702.104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002505","article-title":"Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects","volume":"9","author":"Suarez-Carmona","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.105","doi-asserted-by":"crossref","unstructured":"Nadal E , Saleh M , Aix SP , et al . A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer 2023;23. doi:10.1186\/S12885-023-11153-1","DOI":"10.1186\/s12885-023-11153-1"},{"key":"2026050410151183000_14.5.e009702.106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.107","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0632"},{"key":"2026050410151183000_14.5.e009702.108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819889116"},{"key":"2026050410151183000_14.5.e009702.109","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4123"},{"key":"2026050410151183000_14.5.e009702.110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0308"},{"key":"2026050410151183000_14.5.e009702.111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003580","article-title":"Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival","volume":"9","author":"Shah","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007447","article-title":"Targeting integrin \u03b15 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition","volume":"11","author":"Lu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026050410151183000_14.5.e009702.113","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00139-2"},{"key":"2026050410151183000_14.5.e009702.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.08.042"},{"key":"2026050410151183000_14.5.e009702.115","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2973"},{"key":"2026050410151183000_14.5.e009702.116","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182594387"},{"key":"2026050410151183000_14.5.e009702.117","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8527"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:29Z","timestamp":1777914929000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":117,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2024-009702"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009702","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}